Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
MORRISTOWN, N.J., Dec. 01, 2015 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will present at the Oppenheimer 26th Annual Healthcare Conference as follows:
| Date: | Tuesday, December 8, 2015 | ||||
| Time: | 2:10 p.m. EST | ||||
| Location: | The Westin New York Grand Central, NYC | ||||
The presentation will be webcast and available on the Investors section of the Company’s website at http://www.pernixtx.com/investors/webcasts-presentations/. A replay of the webcast will be available for 30 days after the date of the presentation.
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and psychiatry, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force, uses contracted sales organizations to market its non-core, cough and cold products, and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
Investor Relations Sanjay Patel, (800) 793-2145 ext. 1009 Chief Financial Officer [email protected] Lisa Wilson, 212-452-2793 In-Site Communications [email protected] Media Relations Marianne Lambertson, (800) 793-2145 ext. 1012 Vice President, Strategic Development [email protected]
